SBBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SBBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Strongbridge Biopharma's interest expense for the three months ended in Jun. 2021 was $ -0.81 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2021 was $-2.68 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Strongbridge Biopharma's Operating Income for the three months ended in Jun. 2021 was $ -13.07 Mil. Strongbridge Biopharma's Interest Expense for the three months ended in Jun. 2021 was $ -0.81 Mil. Strongbridge Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Strongbridge Biopharma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strongbridge Biopharma Annual Data | |||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||
Interest Expense | Get a 7-Day Free Trial | -0.02 | -4.31 | -12.52 | - | -1.34 |
Strongbridge Biopharma Quarterly Data | ||||||||||||||||||||
Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
Interest Expense | Get a 7-Day Free Trial | -0.25 | -0.52 | -0.56 | -0.78 | -0.81 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strongbridge Biopharma (NAS:SBBP) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Strongbridge Biopharma's Interest Expense for the three months ended in Jun. 2021 was $-0.81 Mil. Its Operating Income for the three months ended in Jun. 2021 was $-13.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2021 was $17.00 Mil.
Strongbridge Biopharma's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as
Strongbridge Biopharma did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Cdk Associates, L.l.c. | 10 percent owner | C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540 |
Bruce Kovner | 10 percent owner | C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022 |
Caxton Corp | 10 percent owner | 731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540 |
John Johnson | director, officer: Chief Executive Officer | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Garheng Kong | director | 712 COLLEGE AVENUE, MENLO PARK CA 94025 |
Jeffrey W Sherman | director | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Marten Steen | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Hilde H Steineger | director | 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
Stephen J Long | officer: Chief Legal Officer | C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974 |
Fredric J. Cohen | officer: Chief Medical Officer | 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053 |
Scott L. Wilhoit | officer: Chief Commercial Officer | 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053 |
Robert Matthew Lutz | officer: Chief Financial Officer | 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
Richard S Kollender | officer: Chief Operating Officer | C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868 |
A Brian Davis | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
From GuruFocus
By Marketwired Marketwired • 02-25-2021
By Marketwired Marketwired • 03-02-2021
By Marketwired Marketwired • 05-06-2021
By PRNewswire PRNewswire • 05-24-2021
By Marketwired Marketwired • 02-16-2021
By Marketwired Marketwired • 07-29-2021
By Marketwired Marketwired • 09-27-2020
By Marketwired Marketwired • 02-03-2021
By Marketwired Marketwired • 01-06-2021
By Marketwired Marketwired • 09-23-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.